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Abstract
Active transport of microRNAs (miRNA) in extracellular vesicles (EV) occurs in disease. Circulating EV-packaged miRNAs in
the serum of stroke patients were compared to stroke mimics with matched cardio- and cerebrovascular risk factors, with
corroboration of results in a pre-clinical model. An unbiased miRNA microarray was performed in stroke vs. stroke mimic
patients (n = 39). Results were validated (n = 173 patients) by real-time quantitative polymerase chain reaction. miRNA expres-
sion was quantified in total serum/EV (n = 5–7) of naïve adult spontaneously hypertensive stroke-prone rats (SHRSP), their
normotensive reference strain (Wistar Kyoto, WKY) and in circulating EV (n = 3), peri-infarct brain (n = 6), or EV derived from
this region (n = 3) in SHRSP following transient middle cerebral artery occlusion (tMCAO). Circulating EV concentration did
not differ between stroke and stroke mimic patients. The microarray identified many altered EV-packaged miRNAs: levels of
miRNA-17-5p, -20b-5p and -93-5p (miRNA-17 family members) and miRNA-27b-3p were significantly (p ≤ 0.05) increased in
stroke vs. stroke mimic patients. Patients with small vessel disease (SVD) consistently had the highest miRNA levels. Circulating
EV concentration was unaltered between naïve SHRSP and WKY but levels of miRNA-17-5p and -93-5p were significantly
increased in SHRSP. tMCAO in SHRSP did not further alter circulating EVmiRNA-17 family member expression and nor did it
change total miRNA-17 family levels in peri-infarct brain tissue or in EV isolated from this region at 24 h post-tMCAO. Changes
in EV packaged miRNA expression was validated in patients with stroke, particularly those with SVD and corroborated pre-
clinically. Together, altered circulating EV levels of miRNA-17 family members may reflect the chronic sequelae underlying
cerebrovascular SVD rather than the acute ischemic stroke itself.
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Introduction
MicroRNAs (miRNAs) are a class of small, single-stranded
regulatory RNAs, which post-transcriptionally regulate bio-
logical processes by modulating expression of target
mRNAs. Over 60% of human protein-coding genes contain
at least one conserved miRNA-binding site and the majority
of protein coding genes are in-part regulated by miRNAs [1],
the biological effects can be significant [2]. miRNA expres-
sion in blood is altered in people who have suffered ischemic
stroke [3–7]. However, because comparisons were typically
made with healthy controls, it is unclear whether these chang-
es reflect stroke itself, risk factors for stroke or comorbid
conditions.
Extracellular vesicles (EV) are lipid bilayer particles of
endosomal origin, secreted as a result of the fusion of
multivesicular bodies and the plasma membrane [8]. EV
may be the primary mode of miRNA transport [9] and
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EV miRNA can mediate paracrine signalling [10]. The
packaging and secretion of miRNAs in EV is active, better
reflecting the pathobiology of disease than miRNAs re-
leased passively following cellular injury/necrosis.
Changes in circulating EV expression of miR-9, miR-124
[11], miR-223 [12], miR-125, miR-422a [13], miR-21 and
miR-30a [7] has been demonstrated in stroke patients but
studies are limited by sample size, choice of control
groups, lack of validation and a targeted/biased approach
to screening.
In this series of studies, we profiled genome-wide circulat-
ing EV miRNA expression in people with suspected ischemic
stroke, validated findings in a larger cohort and assessed
changes in validated miRNAs in pre-clinical studies. We
hypothesised that EV miRNA expression would differ in peo-
ple with stroke compared to those with symptoms mimicking
a stroke (stroke mimics, the non-stroke control group) and by
stroke sub-type.
Materials and Methods
Clinical Study—Patient Recruitment This study was ap-
proved by the Scotland A Research Ethics Committee
(reference number 11/22/0077). All participants gave in-
formed, written consent. All participants were reviewed
within 24 h of first contact by a consultant stroke physi-
cian and discussed by a multi-disciplinary team. Stroke
was diagnosed by consensus where presentation was con-
sistent with stroke and supported by brain imaging. Stroke
sub-type was assigned using criteria developed for the
Trial of Org 10172 in Acute Stroke Treatment (TOAST)
[14]. A non-stroke was diagnosed when presentation was
not consistent with a vascular event and where an alter-
native firm diagnosis was made. These participants were
used as our non-stroke, control group.
Clinical Sample Collection Peripheral blood samples were
collected 48 h post symptom onset. To isolate serum, blood
samples were allowed to clot for 20 min and then centri-
fuged at 3000g for 15 min at 4 °C before storage at −
80 °C.
Preclinical Study—Experimental AnimalsMale spontaneous-
ly hypertensive stroke prone (SHRSP) and their normo-
tensive control, Wistar Kyoto (WKY) rats (270–310 g,
16–18 weeks old) were maintained ‘in-house’ by
brother-sister mating. Research was conducted in accor-
dance with the Animal Scientific Procedures Act 1986
incorporating European Directive 2010/63/EU and com-
pleted under PPL 60/4286. All studies were approved by
the University of Glasgow’s Ethics Review Committee.
Surgical Procedures Rats were randomly allocated to sham
or transient middle cerebral artery occlusion (tMCAO)
procedure groups, anaesthetised (3% isoflurane in oxy-
gen) and artificially ventilated. Four or 5 days prior to
stroke (or sham) surgery, a cranial burr hole was drilled
and durotomy performed [15]. SHRSP rats were subjected
to tMCAO (n = 3–6) by advancing a silicone-coated
monofilament (Doccol Corporation) via the internal carot-
id artery, blocking the origin of the MCA for 45 min
before reperfusion, or sham procedure (n = 3–6) where
the monofilament was advanced but immediately re-
moved. Naïve age-matched WKY and SHRSP rats (n =
5–7) were included as controls.
Sample Collection Animals were terminally anaesthetised
24 h post-tMCAO or sham procedure or at an equivalent
age (naïve). Blood samples were taken by cardiac punc-
ture and serum isolated and stored as described for the
clinical study. The infarct region and the cortical area
immediately adjacent to this (peri-infarct) and equivalent
regions on the contralateral hemisphere were dissected
and immediately stored at − 80 °C.
EV Isolation and Characterisation EV were isolated from
200 μL of serum using total exosome isolation reagent
(Thermo Fisher Scientific) according to manufacturer’s
instructions. Brain-derived EV were isolated according
to protocol [16] with the isolated pellet resuspended in
phosphate-buffered saline. EV were visualised and their
concentration quantified using nanoparticle tracking anal-
ysis (NTA) on a NanoSight LM10 (Malvern) and by
transmission electron microscope (TEM) following resus-
pension in 2% paraformaldehyde. EV were subsequently
fixed onto Formvar-carbon-coated electron microscope
grids according to protocol [17].
RNA Extraction RNA was extracted from serum-derived EV
(human or rat), 50 mg brain tissue, or from brain-derived EV
using the miRNeasy Mini Kit (QIAGEN) according to man-
ufacturer’s instructions with a DNase step performed for tissue
extractions. The RNA concentration and quality was deter-
mined using a NanoDrop™ (ND-1000 spectrophotometer;
Thermo Fisher Scientific).
miRNA OpenArray™ Experimental Design and Statistical
Analysis cDNA was synthesised using the TaqMan™
MicroRNA Reverse Transcription Kit (Applied Biosystems)
according to manufacturer’s instructions (n = 39 patients).
The optimised low-sample input protocol was used [18]. To
prevent systematic bias, samples were randomised across 13
TaqMan™ OpenArray™ Human MicroRNA Panels using R
(https://www.r-project.org/). Then, 10 ng RNAwas loaded into
each reaction and spiked with 2.5 ng of an exogenous spike-in
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miRNA control (Arabidopsis thaliana: ath-miR-159a). cDNA
was stored at − 20 °C until pre-amplification was performed.
cDNA was pre-amplified using TaqMan™ PreAmp Master
Mix and Megaplex™ PreAmp Primer Mix (pool A or B) ac-
cording to manufacturer’s instructions. Pre-amplified cDNA
was subsequently diluted 1:20 using 0.1X Tris-EDTA buffer
(1 mM Tris and 0.1 mM EDTA, pH 8.0) and stored at − 20 °C
until the OpenArray™ experiment was performed. Pre-
amplified cDNA was loaded onto TaqMan™ OpenArray™
Human MicroRNA Panels according to manufacturer’s in-
structions using a QuantStudio™ 12 K Flex AccuFill™
System. Loaded microRNA panels were then placed in an
OpenArray™ real-time PCR instrument and panels underwent
thermal cycling at 50 °C for 2 min, 95 °C for 10 min and 95 °C
for 15 s and 60 °C for 1 min, repeated for another 39 cycles.
In the OpenArray™ study, and validation experiments, the
experimenter was blinded to the patient subtype and unblinded
at data analysis. Data was initially analysed using DataAssist™
software. While all samples were screened for 754 human
miRNA sequences, individual miRNAs were only taken for-
ward for further analysis if detected in ≥ 30% of patients within
any one stroke subtype (93 miRNAs met this criterion). Data
were normalised to the exogenous spike-in control (ath-miR-
159a) and ΔCt values calculated. Comparisons were made first
between ΔCt values of all ischemic stroke patients vs. non-
stroke controls and then between individual stroke subtypes
and non-stroke controls. A two-tailed Student’s unpaired t test
was used. Statistical significance was taken at p < 0.05.
Thirteen miRNAs whose expression was significantly altered,
as assessed by t test, were taken forward for validation.
Table 1 OpenArray™ study patient characteristics
Non-Stroke Stroke p (Fisher’s test)
n % n %
Age and gender n 10 29 NA
Male, % (n) 7 70.0 22 75.9 0.696
Median age [IQR] 70.0 [62.8–84.0] – 73.0 [60.5–79.5] – 0.544✞
Risk factors for ischaemic stroke Hypertension, % (n) 7 70.0 15 51.7 0.464
Atrial fibrillation, % (n) 3 30.0 5 17.2 0.399
Diabetes (type 1 or 2), % (n) 3 30.0 7 24.1 0.696
Hyperlipidaemia, % (n) 3 30.0 9 31.0 1.000
Peripheral vascular disease, % (n) 0 0.0 0 0.0 1.000
Smoker, % (n) 3 30.0 9 31.0 1.000
Ex smoker, % (n) 3 30.0 6 20.7 0.669
Previous stroke, % (n) 2 20.0 4 13.8 0.636
Family history, % (n) 1 10.0 4 13.8 1.000
Medication Recombinant tissue plasminogen activator, % (n) – – 10 34.5 NA
ACE inhibitor, % (n) 4 40.0 5 17.2 0.197
Alpha blocker, % (n) 1 10.0 0 0.0 0.256
Anticoagulant, % (n) 1 10.0 1 3.4 0.452
Antiplatelet, % (n) 6 60.0 8 27.6 0.124
ARB, % (n) 0 0.0 3 10.3 0.556
Beta blocker, % (n) 4 40.0 9 31.0 0.704
Blood pressure treatment, % (n) 7 70.0 15 51.7 0.464
CCB, % (n) 4 40.0 3 10.3 0.057
Loop diuretic, % (n) 3 30.0 4 13.8 0.344
Oral hypoglycaemic drugs, % (n) 2 20.0 2 6.9 0.267
Spironolactone, % (n) 1 10.0 1 3.4 0.452
Statin, % (n) 6 60.0 13 44.8 0.480
Thiazide, % (n) 2 20.0 2 6.9 0.267





Demographical data for the full cohort of patients used in the OpenArray™ study. For dichotomous variables, a Fisher’s exact test was used to assess
differences. For continuous variables, an unpaired two-tailed Student’s t test (✞) or Mann Whitney U test (♦ ) was used
ACE angiotensin-converting enzyme,ARB angiotensin receptor blocker,CCB calcium channel blocker,NIHSSNational Institutes of Health Stroke Scale
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Bioinformatic Analyses miRWalk 2.0 [19] was used to gener-
ate predicted gene targets for each miRNA in the miR-17
family. Targets predicted by seven or more of the databases
used by miRWalk 2.0 software were used. Gene targets were
subsequently uploaded to DAVID Bioinformatics Resources
6.8 [20] and the biological processes tool used to group to-
gether related gene targets.
Quantitative Real-Time PCR Samples from a total of 173 partic-
ipants (including those screened in theOpenArray™ study)were
included in the clinical validation study. Preclinically, expression
of miRNA-17-5p, -20b-5p and -93-5p in naïve WKY and
SHRSP (n = 5–7/group) and in SHRSP subjected to tMCAO
(45 min; n = 3–6) or sham procedure (n = 3–6) was determined.
cDNA was synthesised by RT-PCR from the total RNA of
isolated EV using the TaqMan™ MicroRNA Reverse
Transcription Kit according to manufacturer’s instructions.
Each reaction contained 5 ng Caenorhabditis elegans miR-39
(cel-miR-39) (exogenous spike-in miRNA control) and 5 ng of
sample RNA. cDNA was stored at − 20 °C until used. When
performing qRT-PCR on miRNA isolated from human EV, pre-
amplification was performed using TaqMan™ PreAmp Master
Mix according tomanufacturer’s instructions. To profile miRNA
expression, qRT-PCR was performed using TaqMan™ miRNA
assays according to manufacturer’s instructions. Duplicate reac-
tions were run for each sample on a 384-well plate.
Statistical Analysis When comparing qualitative demographic
variables between groups, Fisher’s exact test was used. A
Student’s t test,Mann-Whitney test or Kruskall-Wallis was used
Table 2 Validation study patient characteristics
Non-Stroke Stroke p (Fisher’s Test)
n % n %
Age and gender N 34 – 139 – NA
Gender: male 19 55.9 90 64.7 0.428
Median age [IQR] 63.5 [53.8–68.0] – 68.0 [57.0–76.0] – 0.055✞
Risk factors for ischaemic stroke Hypertension, % (n) 13 38.2 57 41.0 0.847
Atrial fibrillation, % (n) 3 8.8 27 19.4 0.206
Diabetes (types 1 or 2), % (n) 7 20.6 24 17.3 0.625
Hyperlipidaemia, % (n) 6 17.6 36 25.9 0.378
Peripheral vascular disease, % (n) 2 5.9 1 0.7 0.099
Smoker, % (n) 9 26.5 45 32.4 0.544
Ex-smoker, % (n) 11 32.4 23 16.5 0.053
Previous stroke, % (n) 5 14.7 19 13.7 1.000
Family history, % (n) 4 11.8 22 15.8 0.789
Medication Recombinant tissue plasminogen activator, % (n) – – 39 28.1 NA
ACE inhibitor, % (n) 8 23.5 32 23.0 1.000
Alpha blocker, % (n) 0 0.0 1 0.7 1.000
Anticoagulant, % (n) 2 5.9 8 5.8 1.000
Antiplatelet, % (n) 14 41.2 51 36.7 0.694
ARB, % (n) 1 2.9 9 6.5 0.689
Beta blocker, % (n) 10 29.4 35 25.2 0.664
Blood pressure treatment, % (n) 14 41.2 68 48.9 0.449
CCB, % (n) 5 14.7 25 18.0 0.803
Loop diuretic, % (n) 1 2.9 15 10.8 0.202
Oral hypoglycaemic drugs, % (n) 2 5.9 10 7.2 1.000
Spironolactone, % (n) 1 2.9 2 1.4 0.484
Statin, % (n) 16 47.1 60 43.2 0.704
Thiazide, % (n) 3 8.8 15 10.8 1.000
Stroke status Median baseline NIHSS [IQR] 1 [0–3] – 4 [2–7] – < 0.0001♦
Demographical data for the full cohort of patients used in the validation study. For dichotomous variables, a Fisher’s exact test was used to assess
differences. For continuous variables, an unpaired two-tailed Student’s t test (✞) or Mann Whitney U test (♦) was used
ACE angiotensin-converting enzyme,ARB angiotensin receptor blocker,CCB calcium channel blocker,NIHSSNational Institutes of Health Stroke Scale
Transl. Stroke Res.
to compare quantitative demographic variables across groups.
Relative quantification (RQ; fold change) was calculated fol-
lowing normalisation to exogenous spike-in control miRNA
(cel-miR-39). Data are presented as RQ ± RQmax/RQmin rel-
ative to the expression in the control non-stroke (clinical stud-
ies) or WKY/sham (preclinical studies) group, whose expres-
sion was 1. Expression was first compared in all ischemic
stroke patients vs. non-stroke controls and then between indi-
vidual stroke subtypes and non-stroke controls. An unpaired
two-sample Student’s t test or one-way ANOVA with post
hoc Dunnett’s test was used for the clinical studies. Preclinical
groups were compared using unpaired two-sampled Student’s t
test (with the addition of a Bonferroni’s multiple comparisons
test where appropriate). The data were analysed on the ΔCt
scale. p < 0.05 was deemed statistically significant.
Results
Clinical Study
A total of 173 participants were recruited between 31 January
2012 and 20 April 2014. The OpenArray™ included 39 partic-
ipants: (non-stroke (n = 10), large artery (n = 9), cardioembolic
(n = 10) and small vessel disease (SVD; n = 10) patients). The
validation study included all 173 patients: non-stroke (n = 34)
and stroke (n = 139) patients. The stroke patients were further
split according to TOAST with large artery (n = 22), cardioem-
bolic (n = 40), SVD (n = 37) and unclassified (n= 40). Baseline
characteristics are shown in Table 1 (OpenArray™ population)
and Table 2 (validation cohort). There were no differences in
baseline characteristics between stroke and non-stroke patients
in the OpenArray™ population (Table 1) or in the validation
cohort, although measures of stroke severity were higher in
stroke patients as expected (Table 2). Baseline characteristics
by stroke subtype are shown in Online Resource 1.
EV isolated from serum of non-stroke and ischemic stroke
patients at 48 h post-stroke were visualised by TEM (Fig. 1a)
and size range confirmed byNTA (Fig. 1b). Themean number
of serum-isolated EVof non-stroke and stroke participants did
not differ (stroke 5.2 ± 0.7 × 108 particles/mL vs. non-stroke
2.4 ± 0.4 × 108 particles/mL (t55 = 1.8; p = 0.079) (Fig. 1c).
OpenArray Detects Altered EV miRNA Expression
in Ischemic Stroke Patients
There was significant upregulation of miRNA-27b-3p, -93-
5p and -520b-3p and downregulation of miRNA-660-5p in
EV from all ischemic stroke patients vs. non-stroke con-
trols (Fig. 2). Other miRNAs were altered (up- or
downregulated) in EV from patients with specific stroke
subtypes (Fig. 2); miRNA-20b-5p, -30a-5p and -93-5p
Fig. 1 Extracellular vesicle
visualisation and quantification. a
TEM observation of whole-
mounted EV purified from human
serum by precipitation. b
NanoSight trace for representative
sample is shown. Black trace in-
dicates EV concentration with in-
creasing particle size, and blue
trace shows cumulative percent-
age of EV with increasing particle
size. c Concentration of EV (30–
120 nm) in stroke (n = 48) and
non-stroke (n = 9) patients.
Horizontal bar represents mean.




(large artery); miRNA-218-5p, -520b-3p and -660-5p
(cardioembolic) and miRNA-17-5p, -93-5p, -199a-3p and
-660-5p (SVD). In other cases, miRNA expression ap-
peared to be either ‘switched on’ or ‘switched off’ in EV
from ischemic stroke patients vs. non-stroke controls
(Fig. 2). The 13 miRNAs whose expression appeared al-
tered and that were taken forward for validation in a larger
patient cohort were miRNA-17-5p, -20b-5p, -27b-3p, -
30a-5p, -93-5p, -199a-3p, -218-5p, -223-5p, -376a-3p, -
520b-3p, -549a-3p, -660-5p and -let-7e-5p.
Fig. 2 EV Expression of miRNAs Altered in Stroke Patients
(OpenArray™). miRNA expression in EV from serum of control non-
stroke patients (n = 10), all stroke patients (n = 29) and stroke patients
separated by TOAST subtype: large artery (n = 9), cardioembolic (n =
10) and SVD (n = 10) stroke patients. Changes in EV miRNA expression
were assessed by OpenArray™, data shown are average ΔCt values
following normalisation to spike housekeeper, ath-miR-159a. Arrows
indicate miRNAs taken forward for further investigation
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qRT-PCR Validates OpenArray Results
Of the 13 miRNAs taken forward, expression of miRNA-17-
5p (RQ 1.54 ± 0.15 vs. 1.00 ± 0.16 (t170 = 2.1; p = 0.039);
Fig. 3a), miRNA-20b-5p (RQ 1.66 ± 0.17 vs. 1.00 ± 0.19
(t171 = 2.4; p = 0.017); Fig. 3b) and miRNA-27b-3p (RQ
1.62 ± 0.16 vs. 1.00 ± 0.18 (t169 = 2.4; p = 0.018); Fig. 3c)
were significantly increased in EV isolated from people with
ischemic stroke compared to non-stroke controls with
miRNA-93-5p approaching significance (RQ 1.51 ± 0.15 vs.
1.00 ± 0.18 (t171 = 2.0; p = 0.051); Fig. 3d). Within these val-
idated miRNAs, 3 are within the miRNA-17 family (miRNA-
Fig. 3 Expression of miRNAs in EV from stroke patients. The expression of
hsa-miR-17-5p (a), hsa-miR-20b-5p (b), hsa-miR-27b-3p (c) and hsa-miR-
93-5p (d) was profiled in EV isolated from stroke patients (n = 139) and
compared to expression in non-stroke patients (n= 34). Change in miRNA
expression was assessed at 48 h post-stroke by qRT-PCR and RQ calculated
from ΔΔCt following normalisation to a spike housekeeper miRNA, cel-
miR-39, and compared to the control, non-stroke patients. Data are presented
as RQ ± RQmax/RQmin. Probability values were calculated using unpaired
Student’s t test vs. non-stroke control patients, *p< 0.05.
Fig. 4 EV miR-17 family expression altered by stroke subtype. EV
expression of hsa-miR-17-5p (a), hsa-miR-20b-5p (b), hsa-miR-
27b-3p (c) and hsa-miR-93-5p (d) was profiled in all stroke patients
(n = 139) of which there were large artery (n = 22), cardioembolic
(n = 40), SVD (n = 37) and unclassified (n = 40). Expression was
compared to that of control, non-stroke patients (n = 34). Change
in miRNA expression was assessed at 48 h post-stroke by qRT-
PCR and RQ calculated from ΔΔCt following normalisation to a
spike housekeeper miRNA, cel-miR-39 and compared to non-stroke
control patients. Data are presented as RQ ± RQmax/RQmin.
Probability values were calculated using one-way-ANOVAwith post
hoc Dunnett’s test, *p < 0.05; **p < 0.01
Transl. Stroke Res.
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17-5p, -20b-5p and -93-5p). The expression of the remaining
nine miRNAs did not differ (Online Resource 2).
Expression of these four miRNAs (Fig. 3) differed by
stroke subtype (Fig. 4). Expression was increased in patients
with SVD stroke compared to non-stroke controls: miRNA-
17-5p (RQ 2.15 ± 0.40 vs. 1.00 ± 0.16 (F4,167 = 3.5; p =
0.009)) (Fig. 4a), miRNA-20b-5p (RQ 2.36 ± 0.47 vs. 1.00
± 0.19 (F4,168 = 3.9; p = 0.005)) (Fig. 4b), miRNA-27b-3p
(RQ 2.24 ± 0.39 vs. 1.00 ± 0.15 (F4,166 = 3.4; p = 0.011))
(Fig. 4c) and miRNA-93-5p (RQ 2.23 ± 0.47 vs. 1.00 ± .18
(F4,168 = 3.5; p = 0.009)) (Fig. 4d). There were no differences
between expression in other stroke subtypes and controls.
Bioinformatic analysis of predicted target genes for the
miR-17 family (Fig. 5a) demonstrated many were involved
in pathways related to stroke damage, for example apoptotic
pathways (Fig. 5b), the response to stress/hypoxia (Fig. 5c)
and repair pathways, including neurogenesis and
vasculogenesis (Fig. 5d).
Selected miRNA-17 Family miRNAs Altered in SHRSP
vs. WKY
Characterisation of the circulating EV (Online Resource
3) in naïve WKY and SHRSP demonstrated no significant
difference in the concentration or size of EV in naïve
WKY vs. SHRSP (Online Resource 3b, c). miRNA-17-
5p, -20b-5p and -93-5p, belonging to the miRNA-17 fam-
ily (Fig. 5a), were the focus of the preclinical experi-
ments. Total serum expression of the three miRNA-17
family miRNAs did not differ between naïve WKY and
SHRSP rats (Fig. 6a–c) but EV expression of miRNA-17-
5p (RQ 4.59 ± 1.57 vs. 1.00 ± 0.78 (t8 = 2.4; p = 0.046)
(Fig. 6d)) and miRNA-93-5p (RQ 11.89 ± 3.88 vs. 1.00
± 0.29 (t12 = 6.5; p < 0.0001)) (Fig. 6f)) was significantly
increased in EV from naïve SHRSP vs. WKY. There was
no significant difference in EV expression of miRNA-
20b-5p between naïve SHRSP and WKY (RQ 2.01 ±
0.54 vs. 1.00 ± 0.36 (t8 = 1.8; p = 0.109) (Fig. 6e)).
miRNA-17 Family miRNAs Are Not Altered in SHRSP
EV Post-tMCAO
Experimental stroke in SHRSP resulted in a significant in-
crease in the concentration, but not size, of circulating EV,
24 h after tMCAO compared to naïve WKY rats but not
naïve SHRSP (Online Resource 3b, c). miRNA-17 family
EV miRNAwas not increased following tMCAO in compar-
ison to sham operation in SHRSP rats: miRNA-17-5p (RQ
0.47 ± 0.05 vs. 1.00 ± 0.52, (t4 = 2.2; p = 0.11)) (Fig. 6g),
miRNA-20b-5p (RQ 0.58 ± 0.08 vs. 1.00 ± 0.29, (t4 = 1.9;
p = 0.13)) (Fig. 6h) and miRNA-93-5p (RQ 0.53 ± 0.10 vs.
1.00 ± 0.68, (t4 = 1.2; p = 0.30)) (Fig. 6i).
There was no change in miRNA-17 family expression in
peri-infarct tissue of tMCAO SHRSP compared to sham
SHRSP (Fig. 7). The expression of miRNA-17-5p, -20b-5p
and -93-5p were all unchanged in peri-infarct tissue and
equivalent tissue in the contralateral hemisphere 24 h post-
tMCAO: miRNA-17-5p (ipsilateral RQ 1.19 ± 0.16 vs. 1.00
± 0.08 (t9 = 1.1; p = 0.31) and contralateral RQ 0.83 ± 0.09 vs.
1.00 ± 0.14 (t10 = 1.0; p = 0.34)) (Fig. 7a), miRNA-20b-5p
(ipsilateral RQ 1.11 ± 0.10 vs. 1.00 ± 0.09 (t9 = 0.85; p =
0.41) and contralateral RQ 0.91 ± 0.11 vs. 1.00 ± 0.19 (t10 =
0.48; p = 0.64)) (Fig. 7c) and miRNA-93-5p (ipsilateral RQ
1.18 ± 0.07 vs. 1.00 ± 0.03 (t9 = 2.4; p = 0.039) and contralat-
eral RQ 1.00 ± 0.03 vs. 1.00 ± 0.03 (t10 = 0.07; p = 0.95))
(Fig. 7e).
Brain-derived EV from the peri-infarct region and equiv-
alent region in the contralateral hemisphere were of a com-
parable size (sham 111.8 ± 10.0 nm vs. tMCAO 134.6 ±
5.4 nm) to those found circulating in serum (Online
Resource 3) with no difference between those isolated from
sham SHRSP compared to SHRSP 24 h after tMCAO (t10 =
2.0; p = 0.073). Expression of miR-17 family expression
(miRNA-17-5p, -20b-5p and -93-5p) was unchanged in
brain-derivedEV fromperi-infarctmaterial or the equivalent
region on the contralateral hemisphere 24 h post-tMCAO:
miRNA-17-5p (ipsilateral RQ 1.25 ± 0.08 vs. 1.00 ± 0.56
(t4 = 0.5; p = 0.65) and contralateral RQ 0.90 ± 0.05 vs.
1.00 ± 0.63 (t4 = 0.2; p = 0.84)) (Fig. 7b), miRNA-20b-5p
expression was low and variable (ipsilateral RQ 3.19 ± 0.46
vs. 1.00 ± 0.42 (t4 = 3.1; p = 0.04) and contralateral RQ 0.95
± 0.13 vs. 1.00 ± 0.50 (t4 = 0.12; p = 0.91)) (Fig. 7d) and
miRNA-93-5p (ipsilateral RQ 1.15 ± 0.27 vs. 1.00 ± 0.45
(t4 = 0.34; p = 0.75) and contralateral RQ 0.88 ± 0.25 vs.
1.00 ± 0.25 (t4 = 0.39; p = 0.72)) (Fig. 7f).
Discussion
We found and validated significant alterations in EV expres-
sion of four miRNAs in people with confirmed stroke com-
pared to stroke mimics (non-stroke controls). Three of these
Fig. 5 MiR-17 family miRNAs and targets. a Schematic representing
three polycistronic miRNA clusters: miR-17-92, miR-106a-363 and
miR-106b-25. The miRNAs in each cluster have been colour coded to
represent which miRNA family (grouped according to seed sequence)
each miRNA belongs to. The full miRNA structures for miRNAs -17-
5p, -93-5p and -20b-5p have been given and the seed sequence (nucleo-
tides 2–7) for each highlighted. miRNA targets were primarily selected on
the basis of their complementarity to the seed sequence of any miRNA.
The number of predicted targets involved in apoptotic pathways (b),
cellular response to stress and hypoxia pathways (c) and repair pathways,
including neurogenesis and vasculogenesis (d) have been summarised for
eachmiRNA in the miR-17 family in Venn diagram form. The list of gene
targets summarises those targets that all 3 miRNAs have in common
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miRNAs are part of the same family (miRNA-17 family).
Differences were predominantly driven by increases in people
with SVD stroke. In our pre-clinical study, we found increased
expression of miRNA-17 family members in circulating
compartmentalised EV in SHRSP compared to WKY but
there was no increase in expression following experimental
stroke. These findings raise the possibility that the differences
seen in miRNA-17 expression in our stroke patients reflect the
underlying pathobiology of cerebrovascular and SVD rather
than the acute ischemic stroke (AIS) itself.
There are several differences between our study and previ-
ous stroke studies of miRNA expression. First, we enrolled
Fig. 6 Circulating miR-17 family expression in naïve and post-tMCAO
rats. Total serum expression of miR-17-5p (a), miR-20b-5p (b) and miR-
93-5p (c) was assessed in naïve normotensive WKY and hypertensive
SHRSP rats (n = 5–7/group). EV miRNA expression of miR-17-5p (d),
miR-20b-5p (e) and miR-93-5p (f) was assessed in naïve WKY and
SHRSP rats (n = 5–7/group). EV expression of miR-17-5p (g), miR-
20b-5p (h) and miR-93-5p (i) was assessed in serum of SHRSP rats at
24 h following tMCAO (n = 3) or sham surgery (n = 3). Change in
miRNA expression was assessed by qRT-PCR and RQ calculated from
ΔΔCt following normalisation to a spike housekeeper miRNA, cel-miR-
39, and compared to control (WKY or sham surgery) rats. Data are pre-
sented as RQ ± RQmax/RQmin. Statistical probability of differences in
expression observed were calculated using unpaired two-tailed Student’s t
test vs. control rats: *p < 0.05; ***p < 0.001
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people with suspected ischemic stroke and then established
whether they had suffered a stroke or were stroke mimics.
Thus, in contrast to many other clinical studies, the non-
stroke patient cohort were not ‘healthy’. This increases the
clinical relevance of any findings and makes it more likely
the findings reflect cerebrovascular disease rather than differ-
ences in baseline factors or co-morbid conditions. Groups
were well balanced regarding baseline characteristics such as
age, sex, several key stroke-related risk factors and prescribed
medications. This is crucial given the effect of age and sex on
miRNA expression [21, 22]. Furthermore, within our study,
we found no association between miRNA-17 family expres-
sion levels and stroke risk factors (e.g. age, sex, diabetes).
Previous reports of miRNA expression in EV of stroke pa-
tients are limited by sample size, selection of controls,
differences in baseline characteristics and a targeted approach
to miRNA selection [4, 7, 11, 12]. We performed an unbiased
screen. Interestingly, the number of EV isolated from serum of
stroke patients and non-stroke controls did not differ here, in
contrast to other studies [11, 23]. This may reflect differences
in baseline factors between groups or time to sample collec-
tion from symptom onset. In previous studies, sampling was at
16.5 h [11] or 24 h [23]; while in our study, sampling was at
48 h after symptom onset. Interestingly, in our preclinical
animal model, there was no difference in the size or number
of circulating EV in control (WKY) and hypertensive
(SHRSP) animals. When experimental stroke was performed
on the SHRSP rats, the number of EV was significantly in-
creased compared to normotensive WKY but not naïve
SHRSP. The size remained unchanged. This supports that in
Fig. 7 MiR-17 family expression
in SHRSP brain or brain-derived
EV post-tMCAO. miRNA ex-
pression was determined a, c, e
peri-infarct tissue of SHRSP rats
24 h post-tMCAO or sham sur-
gery (n = 6/group) or b, d, f brain-
derived EV from peri-infarct tis-
sue of SHRSP rats 24 h post-
tMCAO or sham surgery (n = 3/
group) for miR-17-5p (a, b); miR-
20b-5p (c, d) or miR-93-5p (e, f).
Change in miRNA expression
was assessed by qRT-PCR and
RQ calculated from ΔΔCt fol-
lowing normalisation to a spike in
housekeeper miRNA, cel-miR-39,
and compared to sham operated
SHRSP rats. Data are presented as
RQ ± RQmax/RQmin. Statistical
probability of differences in ex-
pression observed were calculated
using unpaired two-tailed
Student’s t test with Bonferroni’s
multiple comparisons test vs.
sham-operated rats
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the SHRSP, a model of SVD, there are no differences in EV
burden compared to the reference strain, similar to what we
see clinically in our heterogenous patient population. The lack
of increase after AIS clinically, may reflect the presence of
SVD in the non-stroke controls resulting in the failure to see
the additional increase in EV number we see in the preclinical
model when compared to the reference normotensive strain.
Of the 13 miRNAs selected for validation by qRT-PCR, 3
were significantly increased in a large AIS patient population:
miRNA-17-5p, -20b-5p and -27b-3p with -93-5p approaching
significance (p = 0.051). Three of these miRNAs belong to the
miRNA-17 family (miRNA-17-5p, -20b-5p and -93-5p).
They are transcribed from different chromosomes (13, 7 and
X, respectively) but have an identical seed sequence important
for target recognition. Total miRNA-17 expression in serum
(rather than EV-compartmentalised) has been shown to be
altered in stroke patients compared to controls with either
vascular risk factors or other neurological disorders [24].
However, there were differences in some important risk fac-
tors and sex in this study. Usingmicroarray, total miRNA-17, -
20b and -93 expression was increased in whole blood samples
from people with stroke, particularly in those with SVD but
these changes were not validated by qRT-PCR or other means,
the sample size was low and controls were healthy [6]. We
found that changes in EV-compartmentalisedmiRNA-17 fam-
ily expression were greatest in people with SVD stroke in
comparison to stroke mimics. We saw no significant differ-
ence in people with large artery, cardioembolic and unclassi-
fied stroke.
In our preclinical animal model, levels of miRNA-17 fam-
ily miRNA (miRNA-17-5p and -93-5p) expression was in-
creased in circulating EV from SHRSP compared to the nor-
motensive WKY strain. However, miRNA-17-5p and -93-5p
levels did not increase further as a result of experimental
stroke in SHRSP in either circulating EV, in the peri-infarct
region or in brain-derived EV isolated from the peri-infarct
region following tMCAO. This suggests the changes in
miRNA-17 family expression reflect the development of ce-
rebrovascular disease, rather than the acute stroke itself or that
the miRNAs have reached a ceiling level in EV in SHRSP.
Alternatively, it may reflect the different time points samples
were taken clinically vs. preclinically with clinical samples
collected at 48 h after AIS whilst preclinical samples were
collected at 24 h after tMCAO. It is recognised that no animal
model definitively reflects human SVD [25] but the SHRSP
recapitulates many features: it demonstrates modest endothe-
lial and perivascular defects, overactive microglia, poor
myelination, non-specific inflammation and blood brain bar-
rier (BBB) changes [26, 27] while lacking white matter
hyperintensities on MRI or vasculopathy in penetrating arte-
rioles [28]. Taken together with our clinical findings, it is
possible that increased miRNA-17 family expression reflects
the development of SVD, rather than the stroke itself.
Bioinformatic analysis of target genes for the miRNA-17
family members using the Database for Annotation,
Visualisation and Integrated Discovery (DAVID; https://
david.ncifcrf.gov/) shows several validated gene targets that
may be involved in either stroke pathophysiology or
cerebrovascular disease. These included targets linked to
programmed cell death and apoptosis, the cellular response
to stress and repair processes such as proliferation,
axonogenesis and angiogenesis. We did not assess changes
in target gene expression in the study as we did not have
access to appropriate tissues.
We also validated changes in circulating levels of EV-
packaged miRNA-27b-3p in the large patient cohort. Again,
changes were most pronounced in those with SVD stroke.
Previously, total miRNA-27b-3p was detected, but not in-
creased, in plasma and cerebrospinal fluid in patients with
stroke (n = 10; 3 days post-event) compared to those with
other neurological diseases (n = 10) [29] although not in the
EV compartment.
Previous studies have demonstrated changes in pack-
aged circulating miRNAs: miRNA-9, -124 [11], -125b, -
422a [13], -223 [12] -21 and -30a [7] in people with stroke.
Of these, only miRNA-30a-5p and -223-5p demonstrated
altered (increased) expression in circulating EV in our
OpenArray™ but failed validation by qRT-PCR (p = 0.06
and 0.057, unpaired t test and Mann-Whitney U test, re-
spectively). Differences in the control group (not matched
for all CV risk factors), the time/type of blood sampling
and EV/exosome isolation method may account for the
disparities between the results of these studies [7, 12] and
the current study. In addition, Chen et al. [12] did not
stipulate if they determined changes in miRNA-223-3p or
-5p strand and so this may account for the differences in
changes reported between the studies.
The strengths of our study include the unbiased approach to
the OpenArray™, validation, control selection and back trans-
lation to preclinical studies. Our study has limitations: in the
OpenArray™, the low sample input protocol had to be used
due to low RNA yields from patient EV samples (10 ng vs.
standard 100 ng input). Thermo Fisher report that using 10 ng
of input RNAwith their adapted protocol will result in detec-
tion of 92% of miRNAs detected using 100 ng input RNA
[18]. Furthermore, the OpenArray™Human Panels each con-
tain 754 unique human miRNA sequences, only a portion of
the total number of miRNAs known to exist (2588 human
sequences listed on miRbase http://www.mirbase.org/cgi-
bin/mirna_summary.pl?org=hsa). It is possible, therefore,
that we have missed changes in potentially important
miRNAs. Normalisation of microarray and qRT-PCR data re-
mains challenging for circulating RNA expression as there is
not a universal reference gene or miRNA for normalisation
[30]. Use of an external control for the OpenArray™ (A.
thaliana miRNA-159a) or qRT-PCR (C. elegans miRNA-39)
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corrected for differences in qPCR efficiency but does not take
into account endogenous differences in miRNA expression.
However, due to the lack of a suitable endogenous control, the
external control used was appropriate.
The SHRSP is the best available spontaneous model of
human SVD [27, 31, 32] but the model has limitations.
SHRSP demonstrate modest endothelial and perivascular de-
fects as early as 5 weeks of age including impaired endothelial
tight junctions, overactive microglia and poor myelination.
They also have non-specific inflammation and blood brain
barrier (BBB) changes [32] which may not be apparent in
sporadic human SVD. We cannot be sure that the differences
in expression in the SHRSP vs. WKY rat reflect SVD as
identified in our human samples.
In summary, we have identified and validated changes in
circulating EV miRNA expression in people with stroke and
in particular, in people with SVD. Increased expression of
multiple miRNAs from the miRNA-17 family was demon-
strated. Similar findings were seen in SHRSP compared to
WKY but experimental stroke did not alter expression. We
hypothesise that changes in miRNA expression reflect the
development of cerebral SVD rather than an acute stroke.
Further studies to confirm the role of the miRNA 17 family
are needed.
Acknowledgements The authors would like to thank all patients who
participated in this study and Mrs. Margaret Mullin for performing the
TEM.
Funding This work was supported by the Medical Research Council
(PhD studentship MR/K500847/1 and New Investigator Research Grant
G1100562), the R.S. MacDonald Charitable Trust and the British Heart
Foundation (FS/15/64/32035 and RE/13/5/30177).
Compliance with Ethical Standards
Conflict of Interest The authors declare that they have no conflict of
interest.
Ethical Approval All applicable international, national, and/or institu-
tional guidelines for the care and use of animals were followed. All
procedures performed in studies involving human participants were in
accordance with the ethical standards of the institutional and/or national
research committee and with the 1964 Helsinki declaration and its later
amendments or comparable ethical standards.
Informed Consent Informed consent was obtained from all individual
participants included in the study.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
Publisher’s Note Springer Nature remains neutral with regard to juris-
dictional claims in published maps and institutional affiliations.
References
1. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian
mRNAs are conserved targets of microRNAs. Genome Res.
2009;19:92–105. https://doi.org/10.1101/gr.082701.108.
2. Flynt AS, Lai EC. Biological principles of microRNA-mediated
regulation: shared themes amid diversity. Nat Rev Genet. 2008;9:
831–42. https://doi.org/10.1038/nrg2455.
3. Jickling GC, Ander BP, Zhan X, Noblett D, Stamova B, Liu D.
MicroRNA expression in peripheral blood cells following acute
ischemic stroke and their predicted gene targets. PLoS One.
2014;9(6):e99283. https://doi.org/10.1371/journal.pone.0099283.
4. Li P, Teng F, Gao F, Zhang M, Wu J, Zhang C. Identification of
circulating MicroRNAs as potential biomarkers for detecting acute
ischemic stroke. Cell Mol Neurobiol. 2015;35(3):433–47. https://
doi.org/10.1007/s10571-014-0139-5.
5. Sepramaniam S, Tan J-R, Tan K-S, DeSilva D, Tavintharan S,
Woon F-P, et al. Circulating MicroRNAs as biomarkers of acute
stroke. Int J Mol Sci. 2014;15(1):1418–32.
6. Tan KS, Armugam A, Sepramaniam S, Lim KY, Setyowati KD,
Wang CW, et al. Expression profile of MicroRNAs in young stroke
patients. PLoS One. 2009;4(11):e7689.
7. WangW, Li DB, Li RY, Zhou X, Yu DJ, Lan XY, et al. Diagnosis of
hyperacute and acute ischaemic stroke: the potential utility of
exosomal MicroRNA-21-5p and MicroRNA-30a-5p. Cerebrovasc
Dis. 2018;45(5–6):204–12.
8. Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle
formation during reticulocyte maturation. Association of plasma
membrane activities with released vesicles (exosomes). J Biol
Chem. 1987;262(19):9412–20.
9. Gallo A, Tandon M, Alevizos I, Illei GG. The majority of
microRNAs detectable in serum and saliva is concentrated in
exosomes. PLoS One. 2012;7(3):e30679.
10. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO.
Exosome-mediated transfer of mRNAs and microRNAs is a novel
mechanism of genetic exchange between cells. Nat Cell Biol.
2007;9(6):654–9 http://www.nature.com/ncb/journal/v9/n6/
suppinfo/ncb1596_S1.html.
11. Ji Q, Ji Y, Peng J, Zhou X, Chen X, Zhao H, et al. Increased brain-
specific MiR-9 andMiR-124 in the serum exosomes of acute ische-
mic stroke patients. PLoS One. 2016;11(9):e0163645. https://doi.
org/10.1371/journal.pone.0163645.
12. Chen Y, Song Y, Huang J, QuM, Zhang Y, Geng J, Zhang Z, Liu J,
Yang GY Increased circulating exosomal miRNA-223 is associated
with acute ischemic stroke. Front Neurol. 2017. https://doi.org/10.
3389/fneur.2017.00057.
13. Li D, Liu J, Wang W, Li R, Yu D, Lan X, et al. Plasma exosomal
miR-422a and miR-125b-2-3p serve as biomarkers for ischemic
stroke. Curr Neurovasc Res. 2017;14(4):330–7. https://doi.org/10.
2174/1567202614666171005153434.
14. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon
DL, et al. Classification of subtype of acute ischemic stroke.
Definitions for use in a multicenter clinical trial. TOAST. Trial of
org 10172 in acute stroke treatment. Stroke. 1993;24(1):35–41.
https://doi.org/10.1161/01.str.24.1.35.
15. Ord ENJ, Shirley R, van Kralingen JC, Graves A, McClure JD,
WilkinsonM, et al. Positive impact of pre-stroke surgery on surviv-
al following transient focal ischemia in hypertensive rats. J
Neurosci Methods. 2012;211(2):305–8.
16. Perez-Gonzalez R, Gauthier SA, Kumar A, Levy E. The exosome
secretory pathway transports amyloid precursor protein carboxyl-
terminal fragments from the cell into the brain extracellular space. J
Biol Chem. 2012;287(51):43108–15. https://doi.org/10.1074/jbc.
M112.404467.
Transl. Stroke Res.
17. Théry C, Amigorena S, Raposo G, Clayton A. Isolation and char-
acterization of exosomes from cell culture supernatants and biolog-
ical fluids. Current Protocols in Cell Biology. John Wiley & Sons,
Inc.; 2006.
18. Technologies L. Application note: optimized protocol with low
sample input for profiling human microRNA using the
OpenArray® platform. 2011.
19. Dweep H, Gretz N. miRWalk2.0: a comprehensive atlas of
microRNA-target interactions. Nat Meth. 2015;12(8):697. https://
doi.org/10.1038/nmeth.3485 http://www.nature.com/nmeth/
journal/v12/n8/abs/nmeth.3485.html#supplementary-information.
20. Huang DW, Sherman BT, Zheng X, Yang J, Imamichi T, Stephens
R, et al. Extracting biological meaning from large gene lists with
DAVID. Curr Protoc Bioinformatics. 2009;27(1):13.1.1–.1. https://
doi.org/10.1002/0471250953.bi1311s27.
21. Lusardi T, Murphy S, Phillips J, Chen Y, Davis C, Young J et al.
MicroRNA responses to focal cerebral ischemia in male and female
mouse brain. Front Mol Neurosci. 2014. https://doi.org/10.3389/
fnmol.2014.00011.
22. Selvamani A, Williams MH, Miranda RC, Sohrabji F. Circulating
miRNA profiles provide a biomarker for severity of stroke out-
comes associated with age and sex in a rat model. Clin Sci.
2014;127(2):77–89.
23. Couch Y, Akbar N, Davis S, Fischer R, Dickens AM, Neuhaus AA,
et al. Inflammatory stroke extracellular vesicles induce macrophage
activation. Stroke. 2017;48(8):2292–6.
24. Kim J-M, Jung K-H, Chu K, Lee S-T, Ban J, Moon J, et al.
Atherosclerosis-related circulating microRNAs as a predictor of
stroke recurrence. Transl Stroke Res. 2015;6(3):191–7. https://doi.
org/10.1007/s12975-015-0390-1.
25. Horsburgh K, Wardlaw JM, van Agtmael T, Allan SM, Ashford
MLJ, Bath Philip M, et al. Small vessels, dementia and chronic
diseases—molecular mechanisms and pathophysiology. Clin Sci.
2018;132(8):851–68.
26. Bailey EL, McBride MW, Beattie W, McClure JD, Graham D,
Dominiczak AF, et al. Differential gene expression in multiple neu-
rological, inflammatory and connective tissue pathways in a spon-
taneous model of human small vessel stroke. Neuropathol Appl
Neurobiol. 2014;40(7):855–72. https://doi.org/10.1111/nan.12116.
27. Hainsworth AH, Markus HS. Do in vivo experimental models re-
flect human cerebral small vessel disease? A systematic review. J
Cereb Blood Flow Metab. 2008;28(12):1877–91. https://doi.org/
10.1038/jcbfm.2008.91.
28. Brittain JF, McCabe C, Khatun H, Kaushal N, Bridges LR, Holmes
WM, et al. AnMRI-histological study of white matter in stroke-free
SHRSP. J Cereb Blood FlowMetab. 2013;33(5):760–3. https://doi.
org/10.1038/jcbfm.2013.14.
29. Sørensen SS, Nygaard A-B, Nielsen M-Y, Jensen K, Christensen T.
miRNA expression profiles in cerebrospinal fluid and blood of
patients with acute ischemic stroke. Transl Stroke Res. 2014;5(6):
711–8. https://doi.org/10.1007/s12975-014-0364-8.
30. Jarry J, Schadendorf D, Greenwood C, Spatz A, van Kempen LC.
The validity of circulating microRNAs in oncology: five years of
challenges and contradictions. Mol Oncol. 2014;8(4):819–29.
https://doi.org/10.1016/j.molonc.2014.02.009.
31. Bailey EL, McCulloch J, Sudlow C, Wardlaw JM. Potential animal
models of lacunar stroke. Stroke. 2009;40(6):e451–8.
32. Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic ce-
rebral small vessel disease: insights from neuroimaging. Lancet
Neurol. 2013;12(5):483–97. https://doi.org/10.1016/S1474-
4422(13)70060-7.
Transl. Stroke Res.
